On Monday, starting at noon Eastern Time, Avigen (AVGN) will begin webcasting a 3-hour symposium titled "Gene Therapy and CNS Disorders: New Treatment Paradigms Addressing Old Line Illnesses." The symposium will feature leading academic and Avigen scientists, doctors and clinicians presenting an overview of their current research and clinical plans in Parkinson's Disease and Neuropathic Pain.
<<after extensive preclinical research, Avigen filed an Investigational New Drug (IND) application seeking clearance to begin clinical testing of AV201, a gene therapy product for the treatment of Parkinson's disease. In addition, Avigen has obtained an exclusive license to new technology for the treatment of severe chronic pain. This approach represents a new paradigm in understanding the genesis and nature of severe chronic pain, with demonstrated success in treating neuropathic pain in established animal models. The Avigen symposium will review the new Avigen programs and the potential they represent for the millions of patients who suffer from these conditions.
To listen to the webcast follow this URL link: vcall.com .
Confirmed speakers (and topics) for the symposium include:
-- John Monahan, Ph.D., Avigen's President and CEO
(Company Overview)
-- Michael Aminoff, M.D., D.Sc., Professor of Neurology and Director of
the Parkinson's Disease Clinic and Clinical Research Center, University
of California San Francisco. Dr. Aminoff is also the Principal
Investigator for Avigen's proposed clinical trial of AV201 for the
treatment of Parkinson's disease:
(Parkinson's Disease and Problems with Current Treatment Options)
-- John Forsayeth, Ph.D., Avigen's Director of Neurobiology:
(The AV201 Parkinson's Program)
-- Dawn McGuire, M.D., Avigen's Chief Medical Officer:
(Chronic Neuropathic Pain and Challenges with Current Treatments)
-- Linda Watkins, Ph.D., Professor, Department of Psychology, Director of
the Interdepartmental Neuroscience Program, University of Colorado at
Boulder:
(A Novel Approach for Treatment of Neuropathic Pain Using IL-10
Based Gene Therapy)>>
Marc |
